Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 10/2014

01.10.2014 | Review

Caveolin-1 in oral squamous cell carcinoma microenvironment: an overview

verfasst von: Samapika Routray

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Caveolin-1 plays an important role in the pathogenesis of oncogenic cell transformation, tumorigenesis, and metastasis. Increased expression of caveolin-1 in an array of tumors has confirmed its value in prognosis. It has been established that oxidative stress is the main cause for loss of stromal caveolin-1 via autophagy in the tumor microenvironment. In this overview, we attempt to abridge the relationship between caveolin-1 and oral squamous cell carcinoma, taking all the established theories into consideration.
Literatur
1.
Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res. 2005;569:75–85.CrossRefPubMed
2.
Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139–47.CrossRefPubMed
3.
4.
Patra SK. Dissecting lipid raft facilitated cell signalling pathways in cancer. Biochim Biophys Acta. 2008;1785(2):182–206.PubMed
5.
Vallejo J, Hardin CD. Caveolin-1 functions as a scaffolding protein for phosphofructokinase in the metabolic organization of vascular smooth muscle. Biochemistry. 2004;43:16224–32.CrossRefPubMed
6.
Vallejo J, Hardin CD. Expression of caveolin-1 in lymphocytes induces caveolae formation and recruitment of phosphofructokinase to the plasma membrane. FASEB J. 2005;19:586–7.PubMed
7.
8.
9.
Palade GE. Fine structure of blood capillaries. J Appl Phys. 1953;24:1424.
10.
11.
Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1(1):31–9.CrossRefPubMed
12.
Staubach S, Hanisch FG. Lipid rafts: signalling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics. 2011;8(2):263–77.CrossRefPubMed
13.
Razani B, Lisanti MP. Caveolins and caveolae: molecular and functional relationships. Exp Cell Res. 2001;271:36–44.CrossRefPubMed
14.
Li WP, Liu P, Pilcher BK, Anderson RG. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci. 2001;114:1397–408.PubMed
15.
Uittenbogaard A, Ying Y, Smart EJ. Characterization of a cytosolic heat-shock protein–caveolin chaperone complex. Involvement in cholesterol trafficking. J Biol Chem. 1998;273:6525–32.CrossRefPubMed
16.
Liu P, Li WP, Machleidt T, Anderson RG. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol. 1999;1:369–75.CrossRefPubMed
17.
Hansen CG, Nichols BJ. Exploring the caves: cavins, caveolins and caveolae. Trends Cell Biol. 2010;20:177–86.CrossRefPubMed
18.
Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–52.CrossRefPubMed
19.
Aoki MN, Amarante MK, Oda JM, Watanabe MA. Caveolin involvement and modulation in breast cancer. Mini Rev Med Chem. 2011;11(13):1143–52.CrossRefPubMed
20.
Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002;54(3):431–67.CrossRefPubMed
21.
Zhang Y, Iwabuchi K, Nunomura S, Hakomori S. Effect of synthetic sialyl 2-1 sphingosine and other glycosylsphingosines on the structure and function of the “glycosphingolipid signaling domain (GSD)” in mouse melanoma B16 cells. Biochemistry. 2000;39(10):2459–68.CrossRefPubMed
22.
23.
Frank PG, Cheung MW-C, Pavlides S, Llaverias G, Park DS, Lisanti MP. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am J Physiol Heart Circ Physiol. 2006;291:H677–86.CrossRefPubMed
24.
Frank PG, Pavlides S, Cheung MW-C, Daumer K, Lisanti MP. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol. 2008;295:C242–8.PubMedCentralCrossRefPubMed
25.
Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005;288:494–506.CrossRef
26.
Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.CrossRefPubMed
27.
Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP. Caveolin-1 expression is down regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry. 2000;39:13916–24.CrossRefPubMed
28.
Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998;16:1391–7.CrossRefPubMed
29.
Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP. Caveolin-1 regulates transforming growth factor (TGF)beta/SMAD signalling through an interaction with the TGFbeta type I receptor. J Biol Chem. 2001;276:6727–38.CrossRefPubMed
30.
Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001.CrossRefPubMed
31.
Br E, Xiangbin X, Christoph R, et al. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 2007;67:8519–26.CrossRef
32.
Alshenawy HA, Ali MA. Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin-β-catenin complex. Ann Diagn Pathol. 2013;17(6):476–82.CrossRefPubMed
33.
Garcı’a AG, del Pozo MA. Caveolin-1 in cell polarization and directional migration. Eur J Cell Biol. 2008;87:641–7.CrossRef
34.
Glenney Jr JR. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem. 1989;264(34):20163–6.PubMed
35.
Tekpli X, Holme JA, Sergent O, Lagadic-Gossmann D. Role for membrane remodelling in cell death: implication for health and disease. Toxicology. 2013;304(8):141–57.CrossRefPubMed
36.
Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4:499–515.CrossRefPubMed
37.
Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M, Tencer L. Caveolin and cancer: a complex relationship. In: Mattson MP, editor. Membrane microdomain signaling lipid rafts in biology and medicine. Totowa: Humana Press; 2005. p. 161–90.CrossRef
38.
Li S, Okamoto T, Chun M, et al. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995;270:15693–701.CrossRefPubMed
39.
Lee H, Volonte D, Galbiati F, et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol. 2000;14:1750–75.CrossRefPubMed
40.
Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6-and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003;278:5794–801.CrossRefPubMed
41.
Schlege A, Arvan P, Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem. 2001;276:4398–408.CrossRef
42.
Fielding CJ, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci U S A. 1997;94:3753–8.PubMedCentralCrossRefPubMed
43.
Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008;27:715–35.CrossRefPubMed
44.
Cerezo A, Guadamillas MC, Goetz JG, et al. The absence of caveolin-1 increases proliferation and anchorage-independent growth by a Rac-dependent, Erkin dependent mechanism. Mol Cell Biol. 2009;29:5046–59.PubMedCentralCrossRefPubMed
45.
Sun J, Gao J, Hu JB, et al. Expression of Cav-1 in tumour cells, rather than in stromal tissue, may promote cervical squamous cell carcinoma proliferation, and correlates with high-risk HPV infection. Oncol Rep. 2012;27(6):1733–40.PubMed
46.
Miotti ESS, Mazzi M, De Santis G, Canevari S, Tomassetti A. Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Exp Cell Res. 2007;313:1307–17.CrossRefPubMed
47.
Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009;8:2420–4.PubMedCentralCrossRefPubMed
48.
Witkiewicz AK, Dasgupta A, Nguyen KH, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther. 2009;8:1167–75.CrossRef
49.
Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174:2023–34.PubMedCentralCrossRefPubMed
50.
Ma X, Liu L, Nie W, et al. Prognostic role of caveolin in breast cancer: a meta analysis. Breast. 2013;22(4):462–9.CrossRefPubMed
51.
Kannan A, Krishnan A, Ali M, Subramaniam S, Halagowder D, Sivasithamparam ND. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer. 2014;50(1):204–15.CrossRefPubMed
52.
Taira J, Higashimoto Y. Caveolin-1 interacts with protein phosphatase 5 and modulates its activity in prostate cancer cells. Biochem Biophys Res Commun. 2013;431(4):724–8.CrossRefPubMed
53.
54.
55.
Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem. 1998;273:32380–3.CrossRefPubMed
56.
Sainz-Jaspeado M, Martin-Liberal J, Lagares-Tena L, Mateo-Lozano S, del GX M, Tirado OM. Caveolin-1 in sarcomas: friend or foe? Oncotarget. 2011;2(4):305–12.PubMedCentralPubMed
57.
Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, et al. Understanding the “lethal” drivers of tumor-stroma co-evolution. Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor microenvironment. Can Biol Ther. 2010;10(6):537–42.CrossRef
58.
Martinez-Outschoorn UE, Trimmer C, Lin Z, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival. Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 2010;9(17):3515–33.PubMedCentralCrossRefPubMed
59.
Bakhshi FR, Shinin V, Mao M, et al. Role of oxidative stress-induced caveolin-1 S nitrosylation, ubiquitination, and degradation in endothelial cell dedifferentiation and idiopathic pulmonary arterial hypertension. Nitric Oxide. 2013;31(1):S42.CrossRef
60.
Sanguinetti AR, Mastick CC. c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cell Signal. 2003;15(3):289–98.CrossRefPubMed
61.
Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y, Chanvorachote P. Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation. Am J Physiol Cell Physiol. 2011;300:C235–45.PubMedCentralCrossRefPubMed
62.
Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 2003;32(8):461–7.CrossRefPubMed
63.
Han SE, Park KH, Lee G, Huh YJ, Min BM. Mutation and aberrant expression of caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol. 2004;24(2):435–40.PubMed
64.
Xue J, Chen H, Diao L, Chen X, Xia D. Expression of caveolin-1 in tongue squamous cell carcinoma by quantum dots. Eur J Histochem. 2010;54(2):e20.PubMedCentralCrossRefPubMed
65.
Bau DT, Tsai MH, Tsou YA, et al. The association of caveolin-1 genotypes with oral cancer susceptibility in Taiwan. Ann Surg Oncol. 2011;18(5):1431–8.CrossRefPubMed
66.
Nakatani K, Wada T, Nakamura M, Uzawa K, Tanzawa H, Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(7):445–52.CrossRefPubMed
67.
Zhang H, Su L, Müller S, et al. Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer. 2008;99(10):1684–94.PubMedCentralCrossRefPubMed
68.
Masuelli L, Budillon A, Marzocchella L, et al. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 2012;227(9):3344–53.CrossRefPubMed
69.
Masood R, Hochstim C, Cervenka B, et al. A novel orthotopic mouse model of head and neck cancer and lymph node metastasis. Oncogenesis. 2013;9:2:e68.
70.
Nohata N, Hanazawa T, Kikkawa N, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol. 2011;38:209–17.PubMed
71.
72.
Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle. 2010;9(10):1960–71.CrossRefPubMed
73.
Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NFkappaB. Cell Death Differ. 2006;13:759–72.CrossRefPubMed
74.
Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun. 2005;338:617–26.CrossRefPubMed
75.
Bellot G, Garcia-Medina R, Gounon P, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;29:2570–81.PubMedCentralCrossRefPubMed
76.
Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010;9:2423–33.CrossRefPubMed
77.
Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–20.CrossRefPubMed
78.
79.
Podar K, Tai YT, Cole CE, et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004;64:7500–6.CrossRefPubMed
80.
Sáinz-Jaspeado M, Lagares-Tena L, Lasheras J, et al. Caveolin-1 modulates the ability of Ewing’s sarcoma to metastasize. Mol Cancer Res. 2010;8:1489–500.PubMedCentralCrossRefPubMed
81.
Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003;4:31–9.CrossRefPubMed
82.
Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem Sci. 2000;25:530–4.CrossRefPubMed
Metadaten
Titel
Caveolin-1 in oral squamous cell carcinoma microenvironment: an overview
verfasst von
Samapika Routray
Publikationsdatum
01.10.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2482-z

Weitere Artikel der Ausgabe 10/2014

Tumor Biology 10/2014 Zur Ausgabe

Research Article

Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma

Research Article

Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma

Research Article

Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer

Research Article

Overexpression of RFC3 is correlated with ovarian tumor development and poor prognosis

Review

Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives

Research Article

MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise